Home / Market News / $CRMD
fiscal.ai Corporate Catalyst Impact 85/100 ● negative

CorMedix Reports Third Quarter 2026 Financial Results and Provides Business Update

Nov 12, 2026, 2:09 PM UTC · Primary ticker $CRMD

CorMedix reported Q3 2026 revenue exceeding consensus, but a net loss was driven by non-cash expenses from the Melinta acquisition. The company also provided updates on its Heron Therapeutics asset acquisition and FDA review of REZZAYO, indicating potential future growth drivers.

CorMedix announced third-quarter 2026 financial results, reporting revenue of $54.5 million, which surpassed analyst expectations. Despite the revenue beat, the company posted a net loss of $14.7 million, primarily due to a significant non-cash expense related to the remeasurement of contingent consideration from its Melinta Therapeutics acquisition. This indicates that while operational performance (as suggested by adjusted EBITDA of $3.1 million) was solid, accounting adjustments from past M&A impacted the bottom line. The update on the Heron Therapeutics asset acquisition and the FDA's acceptance of the REZZAYO sNDA for an expanded indication are key future catalysts. For traders, the short-term focus will be on how the market weighs the revenue beat and positive adjusted EBITDA against the reported net loss, while long-term opportunities lie in the successful integration of Heron assets and the potential approval of REZZAYO's expanded indication.

$CRMD positive Revenue beat, positive adjusted EBITDA, future growth catalysts
$MLNT neutral Acquired by CorMedix, non-cash impact on acquirer
$HRTX neutral Assets being acquired by CorMedix, deal closing soon
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.